"Shortage of professionals with expertise in both AI and life sciences complicates adoption"

With its ability to both generate insights and act on them autonomously, agentic AI is poised to revolutionise the process of developing new therapies and bringing them to the market.

- Dr Manbeena Chawla

Mohit Sood, Regional Managing Principal (India), ZS

Across every stage of the value chain, from R&D to manufacturing to commercialisation, agentic AI is already having a significant impact. This evolution is particularly pertinent to India's dynamic life sciences landscape, where AI adoption is accelerating rapidly. While traditional AI systems have focused on analysing data and providing insights, agentic AI represents the next frontier. To understand more about the application of agentic AI in India, BioSpectrum spoke to Mohit Sood, Regional Managing Principal at ZS, a global management consulting and technology firm with over 40 years of legacy in transforming healthcare globally. Edited excerpts-

How is agentic AI fundamentally reimagining the life sciences ecosystem?

Agentic AI is revolutionising the life sciences industry by enabling autonomous systems that can plan, execute, and adapt complex tasks across R&D, clinical trials, manufacturing, and regulatory processes. These intelligent agents can rapidly analyse biological data, identify drug targets, design experiments, and even monitor trials in real time. Agentic AI's automation and redesign of commercial processes, such as launch control and omni-channel campaign deployment, significantly enhance efficiency and precision, reducing human error and operational costs. This transformation enables businesses to achieve faster, data-driven decision-making and improved customer engagement.